Research Progress of New Generation EGFR-TKIs after Third-generation

Research Progress of New Generation EGFR-TKIs after Third-generation

Lung cancer has the highest mortality rate in the world. The first- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival time and quality of life of patients with non-small cell lung cancer (NSCLC) to some extent. However, after a...

Full description

Bibliographic Details
Main Authors:	Yuanyuan LIU, Yihui LI, Jiangong WANG
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-11-01
Series:	Chinese Journal of Lung Cancer
Subjects:	lung neoplasms new generation epidermal growth factor receptor-tyrosine kinase inhibitors
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.28

Similar Items

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer
by: Jiamin WANG, et al.
Published: (2023-11-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer
by: Baodong LIU, et al.
Published: (2016-12-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Lianfang NI, et al.
Published: (2018-02-01)

Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs  in Non-small Cell Lung Cancer
by: Shubin LI, et al.
Published: (2018-02-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

Detection and Clinical Significance of Abundance of EGFR Mutation
by: Yi SHAO, et al.
Published: (2017-08-01)

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
by: Fang Wang, et al.
Published: (2019-03-01)

Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
by: Chia-Hao Chang, et al.
Published: (2020-10-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, et al.
Published: (2022-09-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
by: Kunyu Shi, et al.
Published: (2022-07-01)

Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma
by: Zhenhua Li, et al.
Published: (2022-05-01)

Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Chaoyu HONG, et al.
Published: (2016-12-01)

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
by: Tri Le, et al.
Published: (2019-03-01)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
by: Kang Qin, et al.
Published: (2020-04-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Curative Effect of EGFR-TKIs with Anti-angiogenic Drugs as the Treatment for Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer：a Meta-analysis
by: LI Yong, LONG Yong, ZHAO Chong, ZHANG Guanqing, SU Yanhe
Published: (2022-03-01)

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report
by: Satoshi Muto, et al.
Published: (2020-11-01)

Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System  Metastases from Non-small Cell Lung Cancer
by: Yinghua JIN, et al.
Published: (2016-08-01)

Clinical Experience with First-generation Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients  with Brain Metastasis
by: Huixing DONG, et al.
Published: (2017-02-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01)

Analysis of Treatment Response and Chest CT Characteristics for Patients Treated by EGFR-TKI in Relapse Advanced Lung Adenocarcinoma
by: Shuchang CHEN, et al.
Published: (2008-04-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors
by: Wenqiu ZHANG, et al.
Published: (2017-10-01)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of <i>EGFR</i>-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
by: Anastasios Gkountakos, et al.
Published: (2022-01-01)

Efficacy and resistance of EGFR-TKIs for first-line treatment for compound EGFR mutations positive non-small cell lung cancer
by: GUAN Xuhui, et al.
Published: (2022-12-01)

Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor  Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Yuan LI, et al.
Published: (2012-02-01)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
by: Jiannong Li, et al.
Published: (2013-01-01)

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study
by: Jia Hu, et al.
Published: (2022-09-01)